Hospital

Alteplase (Activase) is indicated for the treatment of acute ischemic stroke, acute myocardial infarction, pulmonary embolism, and blocked central venous catheter.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the origin of the historical idea that sexual dysfunction in women is primarily based in emotional and/or psychological conditions.

Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest, discusses the implications of Robert Califf’s appointment to lead the FDA on the future of the agency’s review system.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.

Diane McCarthy, director of biologics pipeline development at US Pharmacopeia (USP), discusses USP’s development of mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.

Facilitating environmental cues that members of the LGBTQ+ community look for to signify that they are in a safe space is an especially important element for the LGBTQ+ community.

The results of 2 analyses in the United Kingdom show a small increase in the potential for intracranial thrombosis after vaccination.

This month's Rx product news features Keytruda, Rituxan, and Cutaquig.

BI 1015550 could treat both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses how hypoactive sexual desire disorder in women was defined and treated historically.

Patients from more socially vulnerable areas were sicker when they arrived at hospitals but did as well as others by the time of discharge, results of a new analysis show.

Glecaprevir and pibrentasvir (Mavyret) is indicated for the treatment of chronic hepatitis C virus genotype 1-6 infections without cirrhosis or with compensated cirrhosis.

Combination netupitant and palonosetron capsules/fosnetupitant and palonosetron for injection (Akynzeo) is indicated to prevent acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy.

Pharmacy technicians can help provide value-added services that save time and even promote patient safety.

Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

Results of the analysis may help inform future COVID-19 vaccine development, investigators say.

The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Hodgkin's lymphoma.

The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.

Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.

During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.

Hospital-onset clostridium difficile infections frequently occur because of both patient and environmental risk factors.

The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.

Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.

The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.